Respiratory virus season remains in full swing, with flu, COVID-19 and respiratory syncytial virus all continuing to pose risks.
Yet most who are eligible for vaccines to moderate these potentially deadly diseases haven’t received them. But experts warn it’s not too late to get one.
Protecting the Most Vulnerable
Newborns and young infants face heightened risks from respiratory infections, including severe illness caused by respiratory syncytial virus. Fortunately, there are also multiple options for reducing their risk.
An RSV vaccine given to pregnant mothers offer critical protection to infants during the first few months of life. The immunity transferred from vaccinated mothers significantly minimizes the risk of severe respiratory illnesses in their newborns.
And for infants whose mothers do not receive the maternal RSV vaccine, or those born prematurely or with underlying health conditions, a monoclonal antibody immunization can offer them an additional layer of protection. These antibodies are designed to prevent severe infection and reduce the chances of hospitalization and death by 80-95%.
The Role of Vaccines
With several weeks of respiratory season still ahead and very high levels of infections around the country, the importance of immunization remains high. In fact, immunization remains one of the most effective tools for reducing severe illness and protecting vulnerable populations, especially infants, from infectious diseases.
By preventing hospitalizations, immunization reduces strain on health systems and communities. At the family level, preventive measures provide a layer of protection and offer peace of mind during what can be a challenging, illness-filled season.
Providers and Parents Should Speak Up
While health care providers should be recommending vaccines for those at greatest risk, patients should also feel empowered to ask for them.
As respiratory season rages on, vaccinations and preventive treatments remain crucial in safeguarding the health of the youngest and most vulnerable.